Oxurion CEO discusses expertise in treating diabetic eye disease and the company’s robust pipeline

Patrik De Haes, MD is CEO of Oxurion (Oxurion.com). Their first major success was cardiac drug tPA; today, Jetrea is their first commercialized product for diabetic eye disease, with three new molecules for diabetic eye disease in development.